SYM FINANCIAL Corp Purchases 543 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

SYM FINANCIAL Corp boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 40.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,880 shares of the company's stock after purchasing an additional 543 shares during the quarter. SYM FINANCIAL Corp's holdings in IDEXX Laboratories were worth $790,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Golden State Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 3,766.7% during the 1st quarter. Golden State Wealth Management LLC now owns 116 shares of the company's stock valued at $49,000 after purchasing an additional 113 shares during the last quarter. Sagespring Wealth Partners LLC bought a new stake in shares of IDEXX Laboratories during the 1st quarter valued at approximately $229,000. Banque Transatlantique SA bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at approximately $2,681,000. Wealth Enhancement Advisory Services LLC grew its holdings in shares of IDEXX Laboratories by 13.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 25,553 shares of the company's stock valued at $10,731,000 after purchasing an additional 2,931 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of IDEXX Laboratories by 42.7% during the 1st quarter. GAMMA Investing LLC now owns 2,187 shares of the company's stock valued at $918,000 after purchasing an additional 654 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price target on the stock. Stifel Nicolaus boosted their target price on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a report on Wednesday, July 2nd. Leerink Partners boosted their target price on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Wall Street Zen raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, July 12th. Finally, Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average target price of $557.88.

IDEXX Laboratories Stock Up 2.8%

IDXX stock traded up $15.22 during midday trading on Friday, reaching $565.19. 1,071,473 shares of the company's stock traded hands, compared to its average volume of 425,413. The company has a market cap of $45.45 billion, a price-to-earnings ratio of 52.24, a P/E/G ratio of 4.00 and a beta of 1.54. The firm's fifty day moving average price is $526.59 and its 200-day moving average price is $466.93. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $568.47.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. During the same quarter in the previous year, the business posted $2.71 EPS. IDEXX Laboratories's quarterly revenue was up 3.6% on a year-over-year basis. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director M Anne Szostak sold 1,260 shares of IDEXX Laboratories stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director owned 1,801 shares in the company, valued at $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.